CLOV

AI Memo

Clover Health Investments

As of 2026-07-09/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-07-09 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

2027 Star-rating recalculation improved payment-year economics • 2027-01-01

Expected move: +8%

Biggest risk

Forward visibility is still only moderate because the thesis depends on sustaining medical-cost performance and SG&A leverage through a much larger member base. The packet does not contain a reliable post-print analyst revision set, and the shares at $4.66 already sit above the packet median target of $4.15, limiting room for multiple expansion if execution wobbles.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

The primary-source setup is better than a generic turnaround story: Q1 delivered positive GAAP earnings, 51% Medicare Advantage membership growth, and maintained a full-year outlook that still implies Clover can finish 2026 with positive GAAP net income [#SEC-8K-2026-05-06]. The June 2026 CMS recalculation adds a plausible 2027 reimbursement tailwind [#8-K-2026-06-18].

Research note

Recommendation

—

Confidence

medium

As of

2026-07-09

Base target

p=45%

Bull target

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next earnings need to confirm medical-cost and SG&A discipline on the larger membership base
2026 first full-year profitability remains the main rerating hook
The primary-source setup is better than a generic turnaround story: Q1 delivered positive GAAP earnings, 51% Medicare Advantage membership growth, and maintained a full-year outlook that still implies Clover can finish 2026 with positive GAAP net income [#SEC-8K-2026-05-06].

BearKey bullets

Coverage remains thin: the packet lacks a dependable set of post-earnings analyst estimate or target revisions, which lowers confidence in how durable the market's positive read will be.
Rapid Medicare Advantage membership growth can expose Clover to unfavorable claims development or utilization surprises if new cohorts mature worse than early indicators suggest.
The profitability thesis still depends on holding SG&A efficiency and benefit expense discipline; Q1 alone does not prove a stable full-year run rate.

WatchKey bullets

2027 Star-rating recalculation improved payment-year economics

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $5 (p=45%)

Bull/Bear spread: +41% / -30%

Vs latest close: Bull +41% · Base +8% · Bear -30%

Scenario probabilities

Bull Target: $6 (p=30%)Base Target: $5 (p=45%)Bear Target: $3 (p=25%)

Commentary

Primary-source tone is positive because the May 6, 2026 earnings release showed profitability and full-year confidence, while the June 18, 2026 8-K added a favorable CMS star-rating recalculation for payment year 2027 [#SEC-8K-2026-05-06] [#8-K-2026-06-18]. Still, news volume in the packet is light, the non-primary coverage is mostly summary-style or retail-oriented, and no robust analyst revision set is available, so this remains a cautious positive-monitoring view rather than a high-conviction call.

As of 2026-07-09 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Next earnings need to confirm medical-cost and SG&A discipline on the larger membership base
2026 first full-year profitability remains the main rerating hook

Scenarios

Bull Target (Scenario probability)

$6 / p=30% prob

Base Target (Scenario probability)

$5 / p=45% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Price $4 as of 2026-07-10

Nearest Scenario: Base (∆ 8%)

Targets vs latest close: Bull +41% · Base +8% · Bear -30%

Sentiment & Exposure

News Sentiment (30d)

0.61

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-01-01
2027 Star-rating recalculation improved payment-year economics
Clover disclosed that CMS recalculated its PPO contract H5141 from 3.5 to 4.5 Stars for payment year 2027 and that HPMS also showed its HMO contract H8010 increasing from 4.0 to 4.5 Stars, which can improve bonus payments and marketing competitiveness if the revised ratings hold [#8-K-2026-06-18].
Prob 74.00% • Move 17.00% • Priced-in 58.00%

Short-term Catalysts

Next few weeks

Next earnings need to confirm medical-cost and SG&A discipline on the larger membership base
2026-11-05
Management said early medical cost trend indicators across both new and returning cohorts were encouraging, but the next report still has to show that benefit expense ratio, claims development, and SG&A leverage remain controlled as rapid Medicare Advantage growth seasons [#SEC-8K-2026-05-06].
Prob 61% • Move 10% • Priced-in 51%

Long-term Catalysts

Months to a year

2026 first full-year profitability remains the main rerating hook
2026-12-31
The Q1 earnings release showed $749.2 million of revenue, $27.3 million of GAAP net income, $40.3 million of adjusted EBITDA, and management said it expects to meet or exceed full-year 2026 outlook including first full-year GAAP net income profitability [#SEC-8K-2026-05-06].
Prob 68% • Move 15% • Priced-in 63%

Risks

Coverage remains thin: the packet lacks a dependable set of post-earnings analyst estimate or target revisions, which lowers confidence in how durable the market's positive read will be.
Rapid Medicare Advantage membership growth can expose Clover to unfavorable claims development or utilization surprises if new cohorts mature worse than early indicators suggest.
The profitability thesis still depends on holding SG&A efficiency and benefit expense discipline; Q1 alone does not prove a stable full-year run rate.
The star-rating benefit is helpful, but its value is mostly a 2027 payment-year issue and remains exposed to CMS processes and Medicare Advantage policy changes [#8-K-2026-06-18].

Peers

Symbol	Summary
PGNY	Progyny is a closer healthcare-services style comp by size than the device names in the packet, but it is still not a direct Medicare Advantage benchmark, so read-through on margins and regulation is limited.
ACHC	Acadia Healthcare is an adjacent services comp from the prior baseline and is somewhat more useful for healthcare-services risk appetite than device peers, though it is still an imprecise operating comp for Clover.
ABT	Abbott is a broad sector comp only and mainly reflects large-cap health-care sentiment rather than Medicare Advantage operating comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-07-09

AI Stock Memo: CLOV - Clover Health Investments - RankAlpha